BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

BIIB upcoming catalysts

Biogen: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 7 readout(s) and 2 FDA event(s). Subscribe to BIIB (.ics).

Drugs: Litifilimab, Felzartamab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-01 est.P3Biogen BIIBNCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Antibody-mediated Rejectionactive not recruiting132

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-11-13FDA approvalapprovedBIOGEN BIIBZURZUVAEApproved 2026-11-13: ZURZUVAE (NDA217369 SUPPL4)
2026-03-27FDA approvalapprovedBIOGEN BIIBSPINRAZAApproved 2026-03-27: SPINRAZA (NDA209531 SUPPL16)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-20 est.P2/P3Biogen BIIBNCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosusactive not recruiting450
2026-09-30 est.P3Biogen BIIBNCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting548
2026-09-27 est.P3Biogen BIIBNCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErytheLupus Erythematosus, Systemicactive not recruiting562
2026-07-30P3Biogen BIIBNCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who TMuscular Atrophy, Spinalcompleted115
2026-03-11P2Biogen BIIBNCT05399888 A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due toMild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementiaactive not recruiting416
2026-03-09P2Biogen BIIBNCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30Parkinson Diseasecompleted650
2026-02-10P2Biogen BIIBNCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing ForRelapsing Forms of Multiple Sclerosiscompleted127

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.